Harrow Q4 2022 Earnings Report $34.22 -0.21 (-0.61%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast Harrow EPS ResultsActual EPS$0.07Consensus EPS -$0.15Beat/MissBeat by +$0.22One Year Ago EPSN/AHarrow Revenue ResultsActual Revenue$20.33 millionExpected Revenue$23.26 millionBeat/MissMissed by -$2.93 millionYoY Revenue GrowthN/AHarrow Announcement DetailsQuarterQ4 2022Date3/23/2023TimeN/AConference Call ResourcesPress ReleaseHROW Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by $2 Trillion Disappears Because of Fed's Secretive New Move (Ad)$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.Click here to see his new research now. Harrow Earnings HeadlinesHarrow's Valuation Hinges On Lofty Growth Amid Persistent Financial StrainsDecember 18, 2024 | seekingalpha.comHarrow: The Triesence RelaunchDecember 14, 2024 | seekingalpha.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.December 22, 2024 | Behind the Markets (Ad)Harrow's Unit Wins Trademark Infringement Case Against OSRXNovember 21, 2024 | markets.businessinsider.comHarrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.November 21, 2024 | finance.yahoo.comHarrow unit gets $34.9M in jury verdict in case of ImprimisRx v. OSRXNovember 21, 2024 | markets.businessinsider.comSee More Harrow Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email. Email Address About HarrowHarrow (NASDAQ:HROW) operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.View Harrow ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
